Effect of Continuous Positive Airway Pressure on Infl ammatory Markers

To the Editor:
Wu and colleagues 1 are to be congratulated on their interesting research recently published in CHEST (February 2010 ) that adds to our understanding of the mechanisms involved in the systemic infl ammatory cascade associated with obstructive sleep apnea. The authors further demonstrated the salutary effects of continuous positive airway pressure (CPAP) in reversing the infl ammatory response.
However, it was disappointing that the therapeutic intervention with CPAP was not described. How did the authors determine the therapeutic pressure setting? What was the mode of CPAP used? Equally important, was compliance with CPAP measured, and if so, was there a correlation between compliance and decrease in infl ammatory mediators? It would have been especially interesting to see a graph of the dose-response curve, specifi cally the degree of CPAP compliance (hours on CPAPրhours of asleep) vs levels of serum high mobility group box-1 protein. Do those data exist, and could they be made available online? 
Response
To the Editor:
We would like to thank Dr Eliasson for his thoughtful and insightful comments regarding our article in CHEST (February 2010). 1 The therapeutic pressure setting for continuous positive airway pressure (CPAP) was determined in the following manner. All patients underwent a standard attended polysomnographic study for CPAP titration with the use of a Sullivan machine (ResMed S8 Escape; Sydney, NSW, Australia) and a comfortably fi tted mask. Initial pressure in the mask was set at 4 cm water and was increased overnight by 1-cm water increments based on the presence of apnea, hypopnea, respiratory effort-related arousals, or snoring associated with arousals. We sought to determine the lowest pressure at which most respiratory events were ablated or the point at which a maximum pressure of 15 cm water was reached with the patient in the supine position and in a rapid-eye-movement sleep period.
2
All patients were educated regarding obstructive sleep apnea syndrome (OSAS) and the proper use of CPAP. A fi xed-pressure CPAP machine was used following the titration. Neither autoadjusting CPAP nor bilevel positive airway pressure was used in this study. The use of CPAP with heated humidifi cation at the effective fi xed-pressure mode every night was strongly encouraged, and most patients applied the heated humidifi cation as suggested.
In our study, the correlation between compliance with CPAP use and decrease in infl ammatory mediators was not taken into consideration. All of the patients had received recent diagnoses of moderately severe or severe OSAS and were naive to nasal CPAP treatment. They had to tolerate nasal CPAP therapy with two complete 4-week follow-up periods. Their usage diaries indicated that most had a good adherence to nasal CPAP (using CPAP . 4 hրd and . 5 dրwk). For some patients, information on the hours of use per day and percentage of days of use could be obtained when a downloadable data card was inserted into the CPAP machine. For others, the patients self-reported CPAP use during clinic follow-up. Therefore, we have incomplete data to generate the dose-response curve of hours on CPAP vs levels of serum high mobility group box-1 protein. 
